Data from new CMS dashboards reveal that many of the drugs that have seen the highest annual growth in spending per beneficiary over the 2012 to 2016 period are products that either currently face or will soon face biosimilar or follow-on biologic competition.
CMS has released updated versions of its online Drug Spending Dashboards, which are intended to help consumers, researchers, policy makers, and other stakeholders understand how spending on prescription drugs per dosage is changing over time.
This update of the dashboards includes year-over-year spending changes for individual drugs and highlights the drugs prescribed most under Medicare and Medicaid. Data from the dashboards reveal that many of the drugs that have seen the highest annual growth in spending per beneficiary over the 2012 to 2016 period are products that either currently face or will soon face biosimilar or follow-on biologic competition.
Under Medicare Part B, which covers drugs that are generally administered by healthcare providers rather than by patients themselves, spending on innovator infliximab (Remicade) grew by 6.0%, with average monthly per beneficiary spending reaching $1910. Two biosimilars (Renflexis and Inflectra), both of which launched at discounts to Remicade, are FDA approved and currently available.
Spending on innovator rituximab (Rituxan), for which multiple companies are developing biosimilars, grew by 5.6%, with average monthly spending reaching $1985. Spending on pegfilgrastim (Neulasta), which is also targeted by biosimilar developers, grew by 8.5%, with average spending of $1195.
Under Medicare Part D, which generally covers self-administered drugs, several products that have approved (but unlaunched) biosimilars or approved follow-ons were among the products that also saw significant increases in pricing. Spending on adalimumab (in the Humira pen presentation) rose by 18.0% to $2835 per month. Currently, 2 adalimumab biosimilars are approved by the FDA, but neither is expected to launch prior to 2023. Spending on Etanercept (Enbrel) rose by 18.2% to $2741. One etanercept biosimilar has gained the FDA’s approval, but no launch date has been announced, as patents concerning the reference etanercept continue to be the subject of ongoing litigation, a trial for which is slated to begin in September 2018.
The 2 presentations of insulin glargine (Lantus and Lantus Solostar) rose by 18.3% to $209 and 14.2% to $196, respectively. Basaglar, a follow-on insulin glargine, is FDA approved and commercially available, and Lusduna, another follow-on, has been tentatively approved pending the conclusion of patent litigation.
Spending on many of the same drugs increased under Medicaid as well; spending on Humira rose by 17.5%, on Enbrel by 17.6%, on Lantus by 18.7%, and on Lantus Solostar by 14.3% under Medicaid.
In a statement concerning the new dashboards, CMS Administrator Seema Verma said that “Publishing how much individual drugs cost from one year to the next will provide much-needed clarity and will empower patients and doctors with the information they need. As [HHS] Secretary Azar has repeatedly pointed out, for years Medicare incentives have actually encouraged higher list prices for drugs, and this updated and enhanced dashboard is an important step to bringing transparency and accountability to what has been a largely hidden process.”
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.